Stocks and Investing
Stocks and Investing
Wed, December 22, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, December 21, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Neena Bitritto-Garg Maintained (ACAD) at Hold with Increased Target to $30 on, Dec 21st, 2021
Neena Bitritto-Garg of Citigroup, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $28 to $30 on, Dec 21st, 2021.
Neena has made no other calls on ACAD in the last 4 months.
There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, all agree with Neena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
- Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
- Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021
Contributing Sources